1/14/2014 9:06:34 AM
NATICK, Mass., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the presentation of two posters at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal (GI) Cancers Symposium being held January 16-18, 2014 in San Francisco, CA. The posters focus on the potential in GI cancers of lead candidate Selinexor (KPT-330) as well as novel PAK4 inhibitors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by